Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

BRAF T1799A

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

HER-2 amplification + RAS wild-type + BRAF wild-type (9)

BRAF V600K + LDH elevation (3)

BRAF V600E + MSI-H (2)

BRAF V600E + PD-L1 expression (2)

BRAF V600E + PD-L1 expression (2)

BRAF V600E + PIK3CA mutation + SMAD4 mutation + MSI-H/dMMR (2)

BRAF V600E + ROS1 fusion (2)

BRAF mutation + MET amplification (2)

BRAF mutation + MSI-L/dMMR (2)

BRAF mutation + TERT overexpression (2)

BRAF wild-type + HER-2 positive (2)

EZR overexpression + BRAF V600E (2)

IDH1 mutation + BRAF V600E (2)

IDH1 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E (2)

IDH2 mutation + BRAF V600E (2)

IDH2 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E (2)

MSI-H/dMMR + BRAF V600E (2)

PD-L1 expression + NRAS Q61R + BRAF D594N (2)

PD-L1 overexpression + BRAF V600E (2)

RAS wild-type + BRAF wild-type + HER-2 positive (2)

ALK fusion + EGFR exon 19 deletion + BRAF G466V + MAP2K1 F129L (1)

ALK rearrangement + ALK I1171N + ALK V1180L + BRCA2 F2801fs (1)

BRAF E501Q + PD-L1 negative (1)

BRAF V600 + LDH elevation (1)

BRAF V600 + LDH elevation + PD-L1 negative (1)

BRAF V600E + CDKN2A deletion + MYCN amplification (1)

BRAF V600E + CDKN2A deletion + RB1 expression (1)

BRAF V600E + EGFR expression (1)

BRAF V600E + PTEN deletion (1)

BRAF V600E + SOX2 amplification (1)

BRAF V600K + CDKN2A deletion + RB1 expression (1)

BRAF mutation + PD-L1 overexpression (1)

BRAF mutation + TMB-H (1)

BRAF mutation + TMB-L + MSI-L/dMMR (1)

BRAF negative + GKAP1-NTRK2 exon 10-16 in-frame fusion (1)

BRAF wild-type + HGF elevation (1)

CD8 elevation + BRAF V600 (1)

Chr t(11;14) + BRAF mutation (1)

EGFR exon 19 deletion + BRAF G464A (1)

EGFR overexpression + BRAF V600E (1)

EGFR overexpression + BRAF mutation (1)

HER-2 amplification + BRAF wild-type (1)

HR positive + BRAF V600E (1)

KIAA1549-BRAF fusion + MET amplification (1)

KIAA1549-BRAF fusion + PTEN deletion (1)

KRAS wild-type + BRAF V600E (1)

LDH elevation + BRAF mutation (1)

MAP2K1 mutation + BRAF wild-type (1)

MSI-H/dMMR + BRAF Mutation (1)

MSI-H/dMMR + KRAS wild-type + BRAF wild-type (1)

NRAS mutation + BRAF wild-type (1)

PD-L1 expression + BRAF negative (1)

PIK3CA mutation + BRAF wild-type (1)

SEMA6A overexpression + BRAF mutation (1)

SRC overexpression + BRAF V600E (1)

TNFAIP3 overexpression + BRAF mutation (1)

PD-L1 overexpression + BRAF mutation (0)

HER-2 amplification + RAS wild-type + BRAF wild-type (9)

BRAF V600K + LDH elevation (3)

BRAF V600E + MSI-H (2)

BRAF V600E + PD-L1 expression (2)

BRAF V600E + PD-L1 expression (2)

BRAF V600E + PIK3CA mutation + SMAD4 mutation + MSI-H/dMMR (2)

BRAF V600E + ROS1 fusion (2)

BRAF mutation + MET amplification (2)

BRAF mutation + MSI-L/dMMR (2)

BRAF mutation + TERT overexpression (2)

BRAF wild-type + HER-2 positive (2)

EZR overexpression + BRAF V600E (2)

IDH1 mutation + BRAF V600E (2)

IDH1 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E (2)

IDH2 mutation + BRAF V600E (2)

IDH2 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E (2)

MSI-H/dMMR + BRAF V600E (2)

PD-L1 expression + NRAS Q61R + BRAF D594N (2)

PD-L1 overexpression + BRAF V600E (2)

RAS wild-type + BRAF wild-type + HER-2 positive (2)

ALK fusion + EGFR exon 19 deletion + BRAF G466V + MAP2K1 F129L (1)

ALK rearrangement + ALK I1171N + ALK V1180L + BRCA2 F2801fs (1)

BRAF E501Q + PD-L1 negative (1)

BRAF V600 + LDH elevation (1)

BRAF V600 + LDH elevation + PD-L1 negative (1)

BRAF V600E + CDKN2A deletion + MYCN amplification (1)

BRAF V600E + CDKN2A deletion + RB1 expression (1)

BRAF V600E + EGFR expression (1)

BRAF V600E + PTEN deletion (1)

BRAF V600E + SOX2 amplification (1)

BRAF V600K + CDKN2A deletion + RB1 expression (1)

BRAF mutation + PD-L1 overexpression (1)

BRAF mutation + TMB-H (1)

BRAF mutation + TMB-L + MSI-L/dMMR (1)

BRAF negative + GKAP1-NTRK2 exon 10-16 in-frame fusion (1)

BRAF wild-type + HGF elevation (1)

CD8 elevation + BRAF V600 (1)

Chr t(11;14) + BRAF mutation (1)

EGFR exon 19 deletion + BRAF G464A (1)

EGFR overexpression + BRAF V600E (1)

EGFR overexpression + BRAF mutation (1)

HER-2 amplification + BRAF wild-type (1)

HR positive + BRAF V600E (1)

KIAA1549-BRAF fusion + MET amplification (1)

KIAA1549-BRAF fusion + PTEN deletion (1)

KRAS wild-type + BRAF V600E (1)

LDH elevation + BRAF mutation (1)

MAP2K1 mutation + BRAF wild-type (1)

MSI-H/dMMR + BRAF Mutation (1)

MSI-H/dMMR + KRAS wild-type + BRAF wild-type (1)

NRAS mutation + BRAF wild-type (1)

PD-L1 expression + BRAF negative (1)

PIK3CA mutation + BRAF wild-type (1)

SEMA6A overexpression + BRAF mutation (1)

SRC overexpression + BRAF V600E (1)

TNFAIP3 overexpression + BRAF mutation (1)

PD-L1 overexpression + BRAF mutation (0)

›

2years

Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis. (PubMed, Cancer Res)

Although RBMS3 silencing rendered BRAFV600E-driven lung tumors resistant to the effects of dabrafenib plus trametinib, the tumors were sensitive to inhibition of porcupine, an acyltransferase of WNT ligands necessary for their secretion. Analysis of TCGA patient samples revealed that chromosome 3P24, which harbors RBMS3, is frequently lost in NSCLC and correlates with poor prognosis. Collectively, these data reveal the role of RBMS3 as a lung cancer suppressor and suggest RBMS3 silencing may contribute to malignant progression.

2 years ago

Journal

|

BRAF (B-raf proto-oncogene) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCND1 (Cyclin D1) • RBMS3 (RNA Binding Motif Single Stranded Interacting Protein 3)

|

BRAF V600E • BRAF V600 • EGFR L858R • MYC expression • CCND1 expression • BRAF T1799A • CTNNB1 expression

|

Mekinist (trametinib) • Tafinlar (dabrafenib)

2years

PERSONALISED CIRCULATING TUMOUR DNA ANALYSIS IN DIFFERENTIATED THYROID CANCER USING NEXT GENERATION SEQUENCING PANELS (ATA 2022)

The findings of this exciting pilot study support the use of personalised sequencing panels for ctDNA detection in AJCC stage II DTC and above. Further multi‐centre long term (> 5 year) clinical prospective trials are recommended to validate these findings and determine if detection of ctDNA predicts disease free survival or overall survival.

2 years ago

Next-generation sequencing • Circulating tumor DNA

|

BRAF (B-raf proto-oncogene)

|

BRAF V600E • BRAF V600 • BRAF T1799A

over2years

BRAF V600E protect from cell death via inhibition of the mitochondrial permeability transition in papillary and anaplastic thyroid cancers. (PubMed, J Cell Mol Med)

In the mitochondria of BRAF V600E mutant cells, there was an interaction between ERK1/2 and GSKa/ß, while upon BRAF V600E knockdown, interaction of GSKa/ß to ERK was decreased significantly. These results show that in thyroid cancer, BRAF V600E regulates the mitochondrial permeability transition through the pERK-pGSK-CypD pathway to resist death, providing new intervention targets for BRAF V600E mutant tumours.

over 2 years ago

Journal

|

BRAF (B-raf proto-oncogene)

|

BRAF V600E • BRAF V600 • BRAF T1799A